… ACT should indeed be conceptually discriminated from dendritic cell (DC)-based approaches,
which de facto constitute anticancer vaccines (and are never performed in the context of …

… In the above mentioned and discussed Galinpepimut-S trial, GM-CSF was added to the
cancer vaccine to create the same effect. GVAX followed by CRS-207 treatment led to increased …

… Dendritic cell (DC)-based cancer vaccination is an immunotherapy that … trials involving DC
vaccines and outlined the type and stage of cancers, the clinical trial phases, the DC vaccine …

… Dendritic cell vaccination as Postremission treatment to prevent or delay relapse in acute …
by Wilms' tumor 1 antigen-targeted Dendritic cell vaccination. Proc Natl Acad Sci USA 2010;107…

… neoantigen-loaded dendritic cell vaccine and neoantigen-activated T-cell therapy, and used
… ablation in the first stage of a phase II trial (NCT03067493). The primary outcomes were …

… monoclonal antibodies, cancer-specific vaccines, dendritic cell-based interventions and
Toll-like … clinical trials investigating the therapeutic potential of this approach in cancer patients. …

… These therapeutic strategies include highly specific interventions, such as dendritic cell (DC)-based,
peptide-based and DNA-based anticancer vaccines,22-24 as well as relatively non-…

… used at the bedside for treatment or in clinical trials. … dendritic cell (DC) vaccination has
emerged as a novel and potential adjuvant treatment for PDAC. DCs are antigen-presenting cells …

… knowledge gained through murine models will be summarized, with the aim of helping in
the design of efficient DC-based vaccines that can be rapidly translated to human clinical trials. …

… Dendritic cells are immune antigen-presenting cells that play a … for immunotherapy via
dendritic cell vaccinations (DCVs) in … Figure 2 Dendritic cell vaccine studies by phase of trial. …